Enveric Biosciences (ENVB) Non Operating Income (2016 - 2026)
Enveric Biosciences (ENVB) posted Non Operating Income of -$303.0 for Q1 2026, down 22.18% sequentially from -$248.0 in Q4 2025, and down 111.8% YoY from $2567.0 in Q1 2025.
Enveric Biosciences (ENVB) Non Operating Income (2016 - 2026) Analysis & Trends
Enveric Biosciences has reported Non Operating Income for 11 years, with the latest figure at -$303.0 in Q1 2026.
- Quarterly Non Operating Income fell 111.8% year-over-year to -$303.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$409.0 (down 100.88% YoY) and the FY2025 annual result came in at $2461.0, down 96.28% from the prior year.
- Non Operating Income slipped to -$303.0 in Q1 2026 per ENVB's latest filing, from -$248.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $3.2 million in Q3 2022 and troughed at -$1.0 million in Q4 2023.
- A 5-year average of $394805.9 and a median of $18537.0 in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income jumped 295.04% in 2022, then tumbled 149.21% in 2023.
- Over 5 years, Non Operating Income stood at $2.1 million in 2022, then slumped by 149.21% to -$1.0 million in 2023, then surged by 102.56% to $26379.0 in 2024, then plunged by 100.94% to -$248.0 in 2025, then dropped by 22.18% to -$303.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$303.0, -$248.0, and $274.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Enveric Biosciences | 5.42 Mn | -2.87 Mn | - | -292.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -303.00 |
| Dec 31, 2025 | -248.00 |
| Sep 30, 2025 | 274.00 |
| Jun 30, 2025 | -132.00 |
| Mar 31, 2025 | 2,567.00 |
| Dec 31, 2024 | 26,379.00 |
| Sep 30, 2024 | -840.00 |
| Jun 30, 2024 | 18,537.00 |
| Mar 31, 2024 | 22,133.00 |
| Dec 31, 2023 | -1.03 Mn |
| Sep 30, 2023 | 632,774.00 |
| Jun 30, 2023 | -601,046.00 |
| Mar 31, 2023 | 183,151.00 |
| Dec 31, 2022 | 2.09 Mn |
| Sep 30, 2022 | 3.18 Mn |
| Jun 30, 2022 | 1.92 Mn |
| Mar 31, 2022 | 271,831.00 |
| Dec 31, 2021 | 1.42 Mn |
| Sep 30, 2021 | 804,463.00 |
| Jun 30, 2021 | 2.45 Mn |